Structure Therapeutics Inc. business relationships
Companies named in Structure Therapeutics Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Structure Therapeutics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 2% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Layers: GLP-1 & obesity
Named in Structure Therapeutics Inc.’s annual report 4
“Gasherbrum License Agreement with Genentech and Roche” SEC filing
“We are aware of amylin small molecules in preclinical development by: Eli Lilly, Eccogene, Nxera, Iktos/Cube Biotech strategic collaboration, Alveus Therapeutics and Ambrosia Biosciences.” SEC filing
“...ets should be accounted for under the guidance at ASC 610-20, Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets , as this type of transaction did not meet the definition of "ordinary activities" of the Company and Exelixis is not considered a "customer" in this transaction.” SEC filing
“Gasherbrum License Agreement with Genentech and Roche” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.